Plus Therapeutics, Inc., a Houston-based clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the appointment of Kyle Guse, J.D., M.B.A. to the Company’s Board of Directors where he will serve as chair of the Audit Committee and on the Compensation Committee.
“Kyle’s decades of financial, transactional, and operational experience in our industry will make an immediate and positive impact on Plus’ board of directors,” said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. “Furthermore, in his role as audit chair, Kyle will be a force in successfully executing Plus’ ambitious business plan and driving stockholder value.”
Mr. Guse is an executive with 30 years of professional experience leading the world’s most innovative companies. For over a decade, he served as Chief Financial Officer, General Counsel, and Secretary of Atossa Therapeutics, Inc., a NASDAQ-listed company developing a drug to prevent and treat breast cancer, which had previously developed and marketed medical devices, and that owned and operated a CLIA-certified laboratory. He serves as Chief Legal Officer of DDC Enterprise Ltd., a NYSE-listed international consumer foods company.
Formerly, he was a partner and practiced corporate law at several top international law firms. Before that, he was a Certified Public Accountant with a Big 4 accounting firm. He earned his J.D. (cum laude) from Santa Clara University Law School and an M.B.A. from California State University, Sacramento, where he also earned his Bachelor of Science degree.
“Plus Therapeutics has multiple and significant opportunities in both the therapeutics and diagnostics markets with REYOBIQ™ (rhenium Re186 obisbemeda) and CNSide, and I believe it has tremendous potential to make an impact on the market,” said Mr. Guse. “I’m looking forward to collaborating closely with the Board and with management to help bring the Company to its full potential for stockholders, practitioners, and patients.”